https://pittplusme.org/study/1574
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Are you the parent of a child ages 12-17 who has been diagnosed with mild-to-moderate atopic dermatitis (eczema) for at least the last 6 months? If so, your child may be eligible to participate in a study of an experimental cream called ARQ-151 in subjects with atopic dermatitis. Involves at least 5 visits over up to 8 weeks. Compensation is provided.
IRB: SSU00092921B
- Arcutis, Inc. – ARQ-151-212, A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis (Pro00033300)
AGE:
12 - 17
DURATION:
8 weeks
VISITS:
At least 5 in-person visits
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
YES
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.